A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Overview of attention for article published in New England Journal of Medicine, May 2014

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 32 news outlets
blogs: 7 blogs
policy: 6 policy sources
twitter: 54 X users
patent: 75 patents
weibo: 4 weibo users
facebook: 4 Facebook pages

wikipedia: 12 Wikipedia pages
reddit: 1 Redditor
f1000: 1 research highlight platform
video: 1 YouTube creator
guideline: 12 clinical guideline sources
podcasts: 1 podcast

Readers on

mendeley: 1756 Mendeley
citeulike: 2 CiteULike

So far, Altmetric has seen 8 posts from 7 blogs.

Immune mechanisms in fibrotic interstitial lung disease

Cell, 11 Jul 2024

Fibrotic interstitial lung diseases have poor survival rates, with current immunotherapies proving ineffective. This review…

2015 ATS Guidelines on Treatment of IPF Released

PulmCCM, 23 Aug 2015

ATS Releases New Idiopathic Pulmonary Fibrosis Treatment Guidelines Recent Studies Bring New Recommendations by Lekshmi Santhosh…

Idiopathic Pulmonary Fibrosis: Hope, At Last

Bioscience Technology All, 11 Aug 2014

Read more about Idiopathic Pulmonary Fibrosis: Hope, At LastComments

特発性間質性肺炎に対するニンテダニブ、ピルフェニドン、アセチルシステインの効果

takのアメブロ　薬理学などなど。, 05 Jun 2014

特発性間質性肺炎とは、難病情報センターによると、肺の間質を炎症{…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity, including 4 additional blog posts.